Results 301 to 310 of about 172,684 (356)

CNS manifestations in acute and chronic graft-versus-host disease. [PDF]

Brain
Lambert N, Forte F, El Moussaoui M, Monseur J, Raus N, Polushin A, Michonneau D, Shultz C, Hogan WJ, Balaguer-Roselló A, Gil-Perotín S, Brijs J, Chauvet P, Gavriilaki M, Carre M, Dulamea AO, Chalandon Y, Salmenniemi U, Duminuco A, Ram R, García-Cadenas I, Porto G, Nguyen S, Smallbone P, González-Vicent M, Santoro JD, Willems E, Baron F, Servais S, Beguin Y, Maquet P, CNS-GvHD Study Group .   +31 more
europepmc   +1 more source

Regulatory T cell therapy for Graft-versus-Host Disease. [PDF]

Bone Marrow Transplant
Lysandrou M, Kefala D, Vinnakota JM, Savvopoulos N, Zeiser R, Spyridonidis A.   +5 more
europepmc   +1 more source

Oral acute graft-versus-host disease. [PDF]

EJHaem
Teymouri F, Sebastian G, Gem H, Minot SS, Rashidi A.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Graft-versus-Host Disease

New England Journal of Medicine, 1991
Graft-versus-host disease, both acute and chronic, continues to be the major complication of human bone marrow transplantation. Improved posttransplant chemoprophylaxis has reduced the incidence of acute graft-versus-host disease, but the incidence of the chronic form of the disease remains unchanged.
J L, Ferrara, H J, Deeg
openaire   +4 more sources

Graft-versus-host disease

Medicina Clínica (English Edition), 2019
Graft-versus-host disease (GVHD) is the most frequent and potentially fatal complication of an allogeneic hematopoietic progenitor cell transplantation. It appears when immunocompetent T cells from donor origin recognise antigens from recipient origin as foreign. The immune response activates donor T cells and destroys recipient tissues.
David F, Moreno, Joan, Cid
openaire   +2 more sources

Acute graft-versus-host disease

Nature Reviews Disease Primers, 2023
Acute graft-versus-host disease (GVHD) is a common immune complication that can occur after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major health problem in these patients, and is associated with high morbidity and mortality. Acute GVHD is caused by the recognition and the destruction of the recipient tissues and organs
Florent Malard, Ernst Holler, Brenda M. Sandmaier, He Huang, Mohamad Mohty   +4 more
openaire   +2 more sources

Graft-versus-host disease

Current Opinion in Oncology, 1997
Graft-versus-host disease (GVHD) continues to be a major obstacle to the success of allogeneic bone marrow transplantation. Furthermore, several clinical strategies being employed at this time in the field of bone marrow transplantation have had an impact on GVHD.
D C, Marcellus, G B, Vogelsang
openaire   +2 more sources

Chronic Graft-Versus-Host Disease

Oncology Nursing Forum, 2006
Chronic graft-versus-host disease is an important cause of late morbidity and mortality after allogeneic stem cell transplantation. With the renewed interest in its pathophysiology and treatment, this review discusses recent clinical and laboratory advances in this disease. Advances in pathophysiology, the relationship between chronic graft-versus-host
Ellaine, Galbizo, Lori A, Williams
  +7 more sources

Chronic Graft-versus-Host Disease

Current Pharmaceutical Design, 2008
Chronic graft-versus-host disease is the most common late, non-relapse complication of transplantation yet it is also one of the least studied. It is the primary cause of morbidity and mortality of long-term survivors of allogeneic bone marrow transplants. Like acute graft-versus-host disease, it does have a strong antitumor effect. The recent National
Javier, Bolaños-Meade, Georgia B, Vogelsang   +1 more
openaire   +2 more sources